Reproductive technology

HRC Fertility Center Adds Dr. Irene Woo to Its Roster of Prominent Doctors

Retrieved on: 
Tuesday, February 13, 2024
Women, Hospitals, Baby, Maternity, Genetics, LGBTQ+, Practice Management, Health, Consumer, General Health, Gynaecology, Fertility preservation, MD, Reproductive technology, Fertility, IVF, HRC, Empathy, FACOG, Medicine, Patient, Journal, Patient safety, Environment, Diagnosis, Research, Book, Nursing

HRC Fertility Center (HRC), one of the largest providers of advanced fertility treatments based in Southern California, today announced the addition of Irene Woo, MD, FACOG , to its team of award-winning physicians.

Key Points: 
  • HRC Fertility Center (HRC), one of the largest providers of advanced fertility treatments based in Southern California, today announced the addition of Irene Woo, MD, FACOG , to its team of award-winning physicians.
  • Woo, an esteemed and compassionate medical professional holding dual board certifications in Obstetrics and Gynecology and Reproductive Endocrinology and Infertility, has joined the center’s Encino office.
  • “I became part of HRC due to its esteemed reputation and commitment to exemplary medical practices,” said Dr.
  • Woo.

Colossal Biosciences and Save the Elephants Debut First-of-its-Kind Project to Utilize Drones and Machine Learning for Elephant Conservation

Retrieved on: 
Thursday, November 9, 2023
Hardware, Sustainability, Technology, Philanthropy, Other Natural Resources, Environment, Environmental Issues, Environmental Health, Artificial Intelligence, Drones, Natural Resources, Foundation, Software, Internet, Mobile, Wireless, Vertebrate Genomes Project, Save the Elephants, Science and technology in Asia, Crime, Intelligence, Biodiversity, VGP, Behavior, Animal husbandry, Carbon, Genetic code, EEHV, Research, Observation, Multimedia, DNA, Death, Elephant, Growth, Genome, Machine learning, Social behavior, Reproductive technology, Assisted migration, Colossal Biosciences, Animal, Credit, Ecology, Algorithm, AI, Map, Hunting, Management, Colossal, Arctic

(Credit: Colossal Biosciences)

Key Points: 
  • (Credit: Colossal Biosciences)
    In this collaboration, Save the Elephants will deploy a small fleet of drones equipped with high resolution and infrared cameras to capture elephant behavioral data.
  • “The technological sophistication of modern drones, combined with appropriate analysis including the use of Machine Learning and AI expertise, will reveal many novel insights into elephant behavior and ecology.
  • And the better we understand elephants, the more we can help to secure a future for these iconic giants,” said Fritz Vollrath of Save the Elephants.
  • Colossal is working closely with the Save the Elephants team, including CEO Frank Pope and Colossal Scientific Advisor and Save the Elephants Chairman, Fritz Vollrath.

Hamilton Thorne Ltd. Opens the Market

Retrieved on: 
Thursday, September 21, 2023
TSX Venture Exchange, Reproductive technology, TSX, Toronto Stock Exchange, HTL, ART, Research, Software, Mining

TORONTO, Sept. 21, 2023 /PRNewswire/ - David Wolf, Chairman and Chief Executive Officer, Hamilton Thorne Ltd. (TSX: HTL) joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange (TSX), to open the market and celebrate the Company's graduation from TSX Venture Exchange to Toronto Stock Exchange.

Key Points: 
  • TORONTO, Sept. 21, 2023 /PRNewswire/ - David Wolf, Chairman and Chief Executive Officer, Hamilton Thorne Ltd. (TSX: HTL) joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange (TSX), to open the market and celebrate the Company's graduation from TSX Venture Exchange to Toronto Stock Exchange.
  • Hamilton Thorne is a leading global provider of precision instruments, consumables, software and services that reduce cost, increase productivity, improve results and enable breakthroughs in Assisted Reproductive Technologies (ART), research, and cell biology markets.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/hamilton-thorne-ltd-opens-the-m...

Results from the first clinical pilot study using maternal spindle transfer indicate that the technique may have value as a treatment for challenging types of infertility and reveal potential limitations when the method is used for avoidance of mitochondr

Retrieved on: 
Friday, March 17, 2023
DNA, American Society for Reproductive Medicine, Human, Pregnancy, MRTS, University, Life, Reproductive technology, Mitochondrion, Embryo, Infertility, National Authority for Remote Sensing and Space Sciences, Cell, RNA, Cytoplasm, Fertilisation, Female, IVF, Fertility, A-DNA, Patient, Risk, Child, Oregon Health and Science University Center for Women's Health, Oregon Health & Science University, MST, Organelle, Mitochondrial disease, Health, Safety, Egg, Vaccine, Birth control

The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.

Key Points: 
  • The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.
  • Maternal spindle transfer is an advanced laboratory technique that belongs to the family of methods known collectively as mitochondrial replacement therapies (MRTs).
  • The research team aimed to explore, for the first time, the clinical feasibility of the maternal spindle transfer technique in a context of infertility treatment.
  • A definitive assessment of the clinical value of the technique must await future larger, controlled and randomized trials.

Results from the first clinical pilot study using maternal spindle transfer indicate that the technique may have value as a treatment for challenging types of infertility and reveal potential limitations when the method is used for avoidance of mitochondr

Retrieved on: 
Friday, March 17, 2023
DNA, American Society for Reproductive Medicine, Human, Pregnancy, MRTS, University, Life, Reproductive technology, Mitochondrion, Embryo, Infertility, National Authority for Remote Sensing and Space Sciences, Cell, RNA, Cytoplasm, Fertilisation, Female, IVF, Fertility, A-DNA, Patient, Risk, Child, Oregon Health and Science University Center for Women's Health, Oregon Health & Science University, MST, Organelle, Mitochondrial disease, Health, Safety, Egg, Vaccine, Birth control

The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.

Key Points: 
  • The exploratory study provides the first insights into safety and efficacy of maternal spindle transfer in humans, when applied in a context of infertility treatment.
  • Maternal spindle transfer is an advanced laboratory technique that belongs to the family of methods known collectively as mitochondrial replacement therapies (MRTs).
  • The research team aimed to explore, for the first time, the clinical feasibility of the maternal spindle transfer technique in a context of infertility treatment.
  • A definitive assessment of the clinical value of the technique must await future larger, controlled and randomized trials.

Reproductive Medicine Associates Opens First Center in Houston and Expands Access to Outstanding Fertility Care for Texans

Retrieved on: 
Tuesday, February 28, 2023
Reproductive technology, Lone Star, IVF, Andrology, Ice cream, Patient, Fertility, Reproductive medicine, REI, Heart, Research, Journal, Ministry of Research, Innovation and Science, Evidence-Based Veterinary Medicine Association, Innovation, Suite, RMA, IUI, International Women's Day, International Women's Health Coalition, Embryology, Thomas Jefferson, Genetic testing, PGT, Yoga, Birth control, Medical device, Genetics, Infertility

HOUSTON, Feb. 28, 2023 /PRNewswire/ -- Reproductive Medicine Associates recently announced the opening of its newest fertility center in Houston, marking RMA's first expansion into the Lone Star State and adding to an extensive network of clinics around the country.

Key Points: 
  • Medical Director Nola Herlihy, M.D., has dedicated her career to building families through her practice and extensive fertility research with RMA.
  • Her research has been published in the Journal of Assisted Reproduction and Genetics, Fertility and Sterility and other peer-reviewed journals.
  • Individuals and couples worried about financing their fertility treatments should check whether their health insurance plan covers comprehensive reproductive services.
  • If fertility treatments are not covered by their insurer, many employers offer supplemental coverage through benefit providers like Progyny.

Center for Reproductive Medicine Welcomes Fertility Specialist and Published Researcher to its Renowned Team of Providers

Retrieved on: 
Wednesday, February 22, 2023
Society, Reproductive medicine, Female, American Society for Reproductive Medicine, Fertility preservation, Journal, Weill Cornell Medicine, ASRM, Obstetrics, Eastern Virginia Medical School, IUI, Patient, Research, Reproductive technology, Family, Parent, CRM, Genetics, IVF, Winter Park, Genetic testing, REI, American College, Learning, American Association of Clinical Endocrinologists, ACOG, Birth control, Celebration, Central Florida, Gynaecology, Infertility

ORLANDO, Fla., Feb. 22, 2023 /PRNewswire/ -- Center for Reproductive Medicine (CRM), part of the global fertility network, The Prelude Network®, announces the addition of Dr. Seif Sadek to its team of leading fertility providers. The fertility leader also launches today a new website designed to enhance the patient experience and better educate patients on their reproductive options.

Key Points: 
  • The fertility leader also launches today a new website designed to enhance the patient experience and better educate patients on their reproductive options.
  • Based in Central Florida with locations in Celebration and Winter Park, CRM has been providing state-of-the-art fertility care to aspiring parents since 1985.
  • He is a member of ACOG, the American Society of Reproductive Medicine (ASRM), and the Society of Reproductive Endocrinology and Infertility (SREI).
  • In addition to expanding access to quality fertility services through the addition of Dr. Sadek, today CRM launched its new website.

Ivy Fertility Acquires Fertility Associates of Memphis

Retrieved on: 
Tuesday, February 14, 2023
Health, Practice Management, Other Health, Research, Science, Biotechnology, Physician, Assisted reproductive technology, American Fertility Association, Hedera, Patient, Reproductive technology, Infertility, Partnership, Growth, IVF, Dream, MD, Birth control, Nursing, Fertility

Ivy Fertility, a nationally and internationally recognized innovator in the field of advanced reproductive technologies, in-vitro fertilization (IVF), and third-party reproduction, announced today it has acquired Fertility Associates of Memphis.

Key Points: 
  • Ivy Fertility, a nationally and internationally recognized innovator in the field of advanced reproductive technologies, in-vitro fertilization (IVF), and third-party reproduction, announced today it has acquired Fertility Associates of Memphis.
  • Fertility Associates of Memphis has provided compassionate and leading-edge fertility services for thousands of patients struggling with infertility, recurrent pregnancy loss, and reproductive disorders.
  • “Our field of Assisted Reproduction offers hope to so many – and together with Ivy Fertility, we look forward to reaching more people with our expert fertility care.”
    “We have tremendous respect for the trusted and innovative practice built by the physicians at Fertility Associates of Memphis,” said Lisa Van Dolah, CEO of Ivy Fertility.
  • Fertility Associates of Memphis’ collective experience in diagnosing and treating infertility, proven successful outcomes, and compassion make our partnership an ideal fit.”
    Paul Brezina, MD, Partner, and Director of Reproductive Genetics at Fertility Associates of Memphis, said, “We are honored to work alongside such a well-respected team of fertility professionals in Ivy Fertility.

Hamilton Thorne Announces the Acquisition of Microptic, S.L.

Retrieved on: 
Thursday, December 1, 2022
Software, Growth, Fertility clinic, Adjustment, CFO, D, Fertility, EBITDA, TSX, AI, Hand, Machine learning, Quarter, Artificial intelligence, TSX Venture Exchange, Analysis, CASA, Middlesex Savings Bank, European, SEDAR, Reproductive technology, Male, Financial statement, Senior debt, ART, Research, Transaction, HTL, Depreciation, Assisted reproductive technology, Acquisition, Risk management, Security (finance), Bank, Virtual assistant

BEVERLY, Mass. and TORONTO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V: HTL) ("Hamilton Thorne" or the "Company"), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies ("ART") research, and cell biology markets, today announced that it has closed the acquisition (the "Transaction") of Microptic, S.L. ("Microptic") effective as of November 30, 2022.

Key Points: 
  • The Transaction expands Hamilton Thorne's product offerings and provides the Company with profitable operations in the well-established European ART market.
  • Key Benefits of the Transaction:
    "We are excited to welcome our new partners from Microptic to the Hamilton Thorne family.
  • This acquisition enhances our product offerings in AI enabled CASA software, image analysis systems, consumables, and related products.
  • Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, IVFtech, Embryotech Laboratories, Tek-Event brands, and Microptic, through its growing sales force and distributors worldwide.

Hamilton Thorne Reports Financial and Operational Results for the Quarter and Nine Months Ended September 30, 2022

Retrieved on: 
Tuesday, November 22, 2022
Software, Growth, Fertility clinic, Adjustment, Planer, EST, EBITDA, Conference, TSX Venture Exchange, Analysis, Travel, Organic growth, International, Reproductive technology, Financial statement, International Financial Reporting Standards, ART, Research, Investment, Acquisition, Bookkeeping

BEVERLY, Mass. and TORONTO, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Hamilton Thorne Ltd. (TSX-V:HTL), a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies (ART), research, and cell biology markets, today reported financial and operational results for the quarter and nine months ended September 30, 2022.

Key Points: 
  • Mr. Wolf added, Looking forward into the balance of 2022, we continue to feel that we are in a strong position.
  • The Company has scheduled a conference call on Tuesday November 22, 2022 at 9:00 a.m. EST to review highlights of the results.
  • Financial statements and accompanying Management Discussion and Analysis for the periods are available on www.sedar.com and the Hamilton Thorne website.
  • Hamilton Thorne markets its products and services under the Hamilton Thorne, Gynemed, Planer, Tek-Event, IVFtech, and Embryotech Laboratories brands, through its growing sales force and distributors worldwide.